Dividend King Growth Giant: J&J Faces Lilly Challenge
Johnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
Index funds and ETFs each have roles; this note explains when index funds offer a simpler, cost-effective path for many investors.
26,830 articlesJohnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
The U.S. debt crossed 100% of GDP for the first time since 1946, prompting concern over rising interest costs and hou...
The Supreme Court ruling overturning most 2025 tariffs triggers a bigger budget gap. The CBO warns deficits will rise...
JPMorgan's revised target to $134 underscores a brighter backdrop for Bunge as the Viterra deal closes and 2026 biofu...
A JPMorgan client note argues that Strategy may purchase as much as $30 billion of Bitcoin in 2026, placing Bitcoin i...
Three heavyweights are quietly reshaping how money moves across borders. Ripple, SWIFT and Visa are testing new rails...
A marquee deal between Berkshire Hathaway and Taylor Morrison could transform how homes are financed, built, and insu...
Strategy has boosted its Bitcoin holdings again, financing the move by selling stock and growing its asset base. Crit...
Gen X is turning to facelifts as GLP-1 weight-loss drugs reshape faces, pushing middle-aged adults to consider surgic...
As Solana enters a two-decade horizon, this article examines how AI-driven finance and real-world asset tokenization ...
Investors eyeing $20,000 a month in dividend income must balance capital, yield, and risk as market conditions shift ...
The U.S. Securities and Exchange Commission seeks a $10 million civil penalty to Rainberry Inc. and appears to dismis...